← Back to Clinical Trials
Recruiting NCT06420206

NCT06420206 Goals of Care Discussion for Patients With Advanced Lung and Gastrointestinal Cancer in the Emergency Department of a Comprehensive Cancer Center

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06420206
Status Recruiting
Phase
Sponsor M.D. Anderson Cancer Center
Condition Lung Cancer
Study Type INTERVENTIONAL
Enrollment 200 participants
Start Date 2024-05-14
Primary Completion 2027-02-02

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Standard of Care (Acute Cancer Care Center)Standard of Care (Goals of Care)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 200 participants in total. It began in 2024-05-14 with a primary completion date of 2027-02-02.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

To improve quality of life for participants with advanced cancer, support their families, and lower overall cost of care.

Eligibility Criteria

Inclusion Criteria: 1. Participant is at least 18 years old presenting to the triage area of the MDACC ACCC for treatment 2. Participant has advanced lung or GI cancer. Advanced cancer patient defined as: locally recurrent or metastatic for which there is no curative treatment available. 3. Participant screens positive for at least 2 of 3 triple threat conditions (dyspnea, altered mental status, or poor performance status) 4. Participant has the ability to speak and write in English 5. Participant has the ability to provide consent OR is accompanied by a LAR able to provide consent Exclusion Criteria: 1. Participant is already enrolled in hospice 2. Participant is comatose 3. Participant has severe intellectual disability 4. Participant has a history of dementia documented in the medical records 5. Participant has baseline communication barriers such as aphasia or deafness 6. Participant is new to MDACC, without established oncology care at our institution at time of ACCC arrival 7. Participant is 18 years or older, currently cared for by pediatrics service 8. Pregnant women 9. Prisoners

Contact & Investigator

Central Contact

Ahmed Elsayem, MD,MPH

✉ aelsayem@mdanderson.org

📞 (713) 745-9911

Principal Investigator

Ahmed Elsayem, MD,MPH

PRINCIPAL INVESTIGATOR

M.D. Anderson Cancer Center

Frequently Asked Questions

Who can join the NCT06420206 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06420206 currently recruiting?

Yes, NCT06420206 is actively recruiting participants. Contact the research team at aelsayem@mdanderson.org for enrollment information.

Where is the NCT06420206 trial being conducted?

This trial is being conducted at Houston, United States.

Who is sponsoring the NCT06420206 clinical trial?

NCT06420206 is sponsored by M.D. Anderson Cancer Center. The principal investigator is Ahmed Elsayem, MD,MPH at M.D. Anderson Cancer Center. The trial plans to enroll 200 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology